

David G Menter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8601888/publications.pdf>

Version: 2024-02-01

56
papers

3,141
citations

218381

26
h-index

189595

50
g-index

57
all docs

57
docs citations

57
times ranked

6059
citing authors

#	ARTICLE	IF	CITATIONS
1	The Platelet Lifeline to Cancer: Challenges and Opportunities. <i>Cancer Cell</i> , 2018, 33, 965-983.	7.7	390
2	Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 411-419.	2.3	261
3	Platelets and cancer: a casual or causal relationship: revisited. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 231-269.	2.7	258
4	Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. <i>Clinical Cancer Research</i> , 2018, 24, 1062-1072.	3.2	225
5	Clinical and molecular characterization of early-onset colorectal cancer. <i>Cancer</i> , 2019, 125, 2002-2010.	2.0	212
6	Cyclooxygenase-2 and Cancer Treatment: Understanding the Risk Should Be Worth the Reward. <i>Clinical Cancer Research</i> , 2010, 16, 1384-1390.	3.2	162
7	Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 289-303.	2.7	137
8	Platelet "first responders" in wound response, cancer, and metastasis. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 199-213.	2.7	127
9	N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. <i>Genome Biology</i> , 2017, 18, 98.	3.8	97
10	The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. <i>Gastroenterology</i> , 2020, 159, 2146-2162.e33.	0.6	75
11	Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention. <i>Seminars in Oncology</i> , 2016, 43, 65-77.	0.8	72
12	<i>FBXW7</i> missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 39268-39279.	0.8	69
13	Tumor cell-platelet interactions in vitro and their relationship to in vivo arrest of hematogenously circulating tumor cells. <i>Clinical and Experimental Metastasis</i> , 1987, 5, 65-78.	1.7	68
14	Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. <i>Cancer Cell</i> , 2020, 37, 371-386.e12.	7.7	68
15	ERK2-Dependent Phosphorylation of CSN6 Is Critical in Colorectal Cancer Development. <i>Cancer Cell</i> , 2015, 28, 183-197.	7.7	67
16	Platelets, circulating tumor cells, and the circulome. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 235-248.	2.7	61
17	MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a <i>de novo</i> phenomenon. <i>Oncotarget</i> , 2016, 7, 54627-54631.	0.8	53
18	The somatic mutation landscape of premalignant colorectal adenoma. <i>Gut</i> , 2018, 67, 1299-1305.	6.1	52

#	ARTICLE	IF	CITATIONS
19	Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4146-4154.	3.2	50
20	Back to the Colorectal Cancer Consensus Molecular Subtype Future. <i>Current Gastroenterology Reports</i> , 2019, 21, 5.	1.1	50
21	Validation of HER2 Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	1.5	46
22	The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 1650-1663.	3.2	43
23	Modeling of Patient-Derived Xenografts in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1435-1442.	1.9	40
24	The potential role of platelets in the consensus molecular subtypes of colorectal cancer. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 273-288.	2.7	37
25	Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. <i>Annals of Surgical Oncology</i> , 2017, 24, 4051-4058.	0.7	32
26	Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. <i>British Journal of Cancer</i> , 2019, 121, 505-510.	2.9	32
27	Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019, 120, 340-345.	2.9	29
28	Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. <i>Clinical Cancer Research</i> , 2021, 27, 3039-3049.	3.2	28
29	Real-Time MRI-Guided Catheter Tracking Using Hyperpolarized Silicon Particles. <i>Scientific Reports</i> , 2015, 5, 12842.	1.6	27
30	Endothelial cell malignancies: new insights from the laboratory and clinic. <i>Npj Precision Oncology</i> , 2017, 1, 11.	2.3	27
31	Developing hyperpolarized silicon particles for in vivo MRI targeting of ovarian cancer. <i>Journal of Medical Imaging</i> , 2016, 3, 036001.	0.8	24
32	Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy. <i>Frontiers in Oncology</i> , 2018, 8, 107.	1.3	24
33	Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. <i>Gastroenterology</i> , 2021, 161, 196-210.	0.6	23
34	Microsomal PGE ₂ synthase-1 regulates melanoma cell survival and associates with melanoma disease progression. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 297-308.	1.5	22
35	DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway. <i>Clinical Cancer Research</i> , 2019, 25, 641-651.	3.2	21
36	Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting. <i>Clinical Cancer Research</i> , 2021, 27, 120-130.	3.2	21

#	ARTICLE	IF	CITATIONS
37	CTC analysis: an update on technological progress. <i>Translational Research</i> , 2019, 212, 14-25.	2.2	20
38	Bioactive lipid metabolism in platelet "first responder" and cancer biology. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 439-454.	2.7	14
39	Convergence of Nanotechnology and Cancer Prevention: Are We There Yet?. <i>Cancer Prevention Research</i> , 2014, 7, 973-992.	0.7	11
40	Cyclooxygenase 2 selective inhibitors in cancer treatment and prevention. <i>Expert Opinion on Investigational Drugs</i> , 2002, 11, 1749-1764.	1.9	10
41	Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development. <i>BMC Cancer</i> , 2020, 20, 871.	1.1	9
42	Real-Time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution by Hyperpolarized Magnetic Resonance Spectroscopy. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 4179-4183.	7.2	8
43	Association of PIK3CA mutations (mut) with immune engagement and clinical benefit from immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3604-3604.	0.8	8
44	Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 147-172.	2.7	6
45	Platelets: "First Responders" in Cancer Progression and Metastasis. , 2017, , 1111-1132.		5
46	Methylation-eQTL analysis in cancer research. <i>Bioinformatics</i> , 2021, 37, 4014-4022.	1.8	5
47	Novel markers for liquid biopsies in cancer management: Circulating platelets and extracellular vesicles. <i>Molecular Cancer Therapeutics</i> , 2022, , .	1.9	5
48	The characteristics of ARID1A mutations in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3595-3595.	0.8	4
49	Platelet microparticles: small payloads with profound effects on tumor growth. <i>Non-coding RNA Investigation</i> , 2017, 1, 15-15.	0.6	3
50	The immune impact of PI3K-AKT pathway inhibition in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 154-154.	0.8	2
51	Proteomic profiling of phosphatidylinositol 3-kinase (PI3K) altered metastatic colorectal cancer (mCRC) after protein kinase B (Akt) inhibition: Insulin like growth factor 1 receptor (IGF1R) mediates adaptive resistance.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3549-3549.	0.8	1
52	Preface. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 193-194.	2.7	0
53	Real-Time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution by Hyperpolarized Magnetic Resonance Spectroscopy. <i>Angewandte Chemie</i> , 2019, 131, 4223-4227.	1.6	0
54	Consensus molecular subtypes (CMS), markers of systemic inflammation (SI) and clinicopathological parameters in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2018, 36, e15600-e15600.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Meat consumption and BRAF mutation status in colorectal cancer.. Journal of Clinical Oncology, 2019, 37, e15135-e15135.	0.8	0
56	HER3 expression in metastatic colorectal cancer: Defining the clinicomolecular profile of an emerging target.. Journal of Clinical Oncology, 2022, 40, 3588-3588.	0.8	0